Celltrion's 'Omlyclo' Reaches 30% Market Share in Europe One Year After Launch

'Aptozma' also reaches 13% market share
Remsima IV and SC also maintain solid momentum

Celltrion's high-margin new products are rapidly gaining ground in Europe. Omlyclo, a treatment for allergic diseases, surpassed a 30% market share in Europe just over a year after its launch. Its established flagship products are also maintaining high market shares, raising expectations that growth will continue through the end of the year.

Product image of Omlyclo, Celltrion's treatment for chronic spontaneous urticaria and allergic diseases. Celltrion.

According to IQVIA, a pharmaceutical market research firm, on October 30, Omlyclo (active ingredient: omalizumab), Celltrion's treatment for chronic spontaneous urticaria and allergic diseases, had a 30% share of the European market in the second quarter of this year. The milestone came just over a year after it became the first omalizumab biosimilar to launch in Europe, in the second half of last year. Among the five major European markets (EU5), it captured a 47% share in the United Kingdom and 25% in Italy. Omlyclo's cumulative sales through the third quarter totaled 320.5 billion won.

Prescriptions for Aptozma (active ingredient: tocilizumab), a treatment for autoimmune diseases, are also rising rapidly. Its European market share reached 13% in the second quarter, nearly doubling from the previous quarter. It recorded shares of 32% in Spain and 66% in Portugal. Steqeyma (active ingredient: ustekinumab) secured a 28% share in Italy after winning tenders from major regional governments, including Tuscany and Emilia-Romagna.

Existing products are also maintaining solid momentum. The Remsima product line (IV and SC) has a 70% share of the European infliximab market and a 77% share in the EU5. Its share in France is as high as 80%. The liquid formulation of Remsima for intravenous injection, launched early this year, is also gaining traction. Celltrion's Netherlands subsidiary signed a supply contract in the third quarter with the country's largest hospital group, which comprises seven university hospitals. Starting in February 2027, it will supply the liquid formulation of Remsima for all infliximab used by the group.

These results were also reflected in Celltrion's third-quarter performance. Sales of its new product portfolio totaled 905.8 billion won in the third quarter, accounting for 67% of its biopharmaceutical sales. Celltrion plans to expand the countries in which it sells and the channels through which it supplies its products by tailoring its direct sales strategy to the characteristics of each national market, with the goal of raising the share of its new product portfolio to 70%.

A Celltrion official said, "As new products such as Omlyclo and Aptozma rapidly establish themselves in Europe and win more tenders, their performance is being confirmed by real-world prescription data. We will focus on winning tenders in key countries and expanding prescriptions at medical institutions to sustain growth beyond the third quarter and through the end of the year."

This content was produced with the assistance of AI translation services.